Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues

Tracy Staton Will Pfizer come back at AstraZeneca? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals. FiercePharma ...

AstraZeneca finally bails on troubled Targacept after years of failure

Damian Garde After 9 years of fruitless work on treatments for Alzheimer's disease and depression, AstraZeneca is dissolving its partnership with Targacept, leaving the battered ...

AstraZeneca crows about Brilinta edge in new ACS treatment guidelines

Tracy Staton Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really ...

Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall’s lung meds

Tracy Staton AstraZeneca has agreed to pay $ 875 million up front–and up to $ 2.2 billion total, with milestones–for Almirall's respiratory portfolio. The deal brings ...

AstraZeneca unit rolls out preemie newspaper ads to fight Synagis limits

Tracy Staton Drugmakers cheer when doctors' groups revise treatment guidelines to include new drugs. What happens when these powerful professional associations change those recommendations ...

AstraZeneca reaches out to Roche with a would-be cancer blockbuster

Damian Garde AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $ 3 billion a year at its peak, and the drugmaker is working ...

AstraZeneca dishes on its $500M new home in Cambridge, U.K.

Damian Garde AstraZeneca's sweeping new Cambridge, U.K., campus will be constructed with collaboration in mind, the company said, unveiling plans for the $ 500 million site it ...

Another Pfizer bid for AstraZeneca? Investors weigh in

Stacy Lawrence A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly ...

How to sell a statin? Pfizer and AstraZeneca have different ideas

Tracy Staton It's a tale of two statin drugs and their attempts to keep market share–or build it, as the case may be. Pfizer rolled out a new version of its Lipitor copay ...

UPDATED: Pfizer hikes bid for AstraZeneca to $117B, swears off hostile maneuver

John Carroll Pfizer has upped its bid for AstraZeneca to £55 a share, or $ 117 billion, hitting the "magic number" that bankers close to these talks ...

AstraZeneca trumpets diabetes duo’s victory in Phase III

Tracy Staton While its top executives were prepping for a hearing on Pfizer's megamerger offer, AstraZeneca rolled out new data from a diabetes trial. The verdict? A combination ...

AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline

Damian Garde Two key investigational drugs came through in mid-stage studies, providing some ballast for the drugmaker as it boasts the value of its pipeline in an effort to ward off ...
Page 3 of 912345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS